Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)

N/ACompletedNCT01099124

Tianjin Medical University Cancer Institute and Hospital25 enrolled

Overview

The purpose of this study is to evaluate safety and tolerance of M2ES with TC regimen in advanced NSCLC.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non Small Cell Lung Cancer

Interventions

M2ESDRUG

polyethylene glycol rh recombinant endostatin

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Aged 18-70 years old; 2. Patients with Ⅲ/Ⅳ NSCLC confirmed by histopathology or cytology who ware naive or previous chemotherapy without TC regimen; 3. No contraindication for chemotherapy; 4. ECOG performance scale 0-2; 5. No history of anti-angiogenesis therapy; 6. Patients are voluntary to participate and sigh the informed contents. Exclusion Criteria: 1. Concurrent use of other anti-cancer agents; 2. Allergic history to M2ES and biological agents; 3. Pregnant or breast-feeding women; 4. With other malignancy; 5. With severe cardiopulmonary disease; 6. Uncontrolled brain metastasis patients; 7. Other conditions that are regarded for exclusion by the trialists.

Locations (1)

Tianjin Medical University Cancer Institude and Hospital

Tianjin, China

Outcomes

Primary Outcomes

Adverse events incidence,including severe adverse events incidence

Time frame: one year

Secondary Outcomes

Tumor response rate and disease controlled rate

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.